Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Differential phosphorylation determines the repressor and activator potencies of GLI1 proteins and their efficiency in modulating the HPV life cycle.

Piirsoo A, Pink A, Kasak L, Kala M, Kasvandik S, Ustav M, Piirsoo M.

PLoS One. 2019 Nov 26;14(11):e0225775. doi: 10.1371/journal.pone.0225775. eCollection 2019.

2.

E2 protein is the major determinant of specificity at the human papillomavirus origin of replication.

Laaneväli A, Ustav M, Ustav E, Piirsoo M.

PLoS One. 2019 Oct 23;14(10):e0224334. doi: 10.1371/journal.pone.0224334. eCollection 2019.

3.

Activity of CK2α protein kinase is required for efficient replication of some HPV types.

Piirsoo A, Piirsoo M, Kala M, Sankovski E, Lototskaja E, Levin V, Salvi M, Ustav M.

PLoS Pathog. 2019 May 15;15(5):e1007788. doi: 10.1371/journal.ppat.1007788. eCollection 2019 May.

4.

The molecular biology and HPV drug responsiveness of cynomolgus macaque papillomaviruses support their use in the development of a relevant in vivo model for antiviral drug testing.

Tombak EM, Männik A, Burk RD, Le Grand R, Ustav E, Ustav M.

PLoS One. 2019 Jan 25;14(1):e0211235. doi: 10.1371/journal.pone.0211235. eCollection 2019.

5.

DNA-launched RNA replicon vaccines induce potent anti-Ebolavirus immune responses that can be further improved by a recombinant MVA boost.

Öhlund P, García-Arriaza J, Zusinaite E, Szurgot I, Männik A, Kraus A, Ustav M, Merits A, Esteban M, Liljeström P, Ljungberg K.

Sci Rep. 2018 Aug 20;8(1):12459. doi: 10.1038/s41598-018-31003-6.

6.

Antibody response against cancer-testis antigens MAGEA4 and MAGEA10 in patients with melanoma.

Õunap K, Kurg K, Võsa L, Maiväli Ü, Teras M, Planken A, Ustav M, Kurg R.

Oncol Lett. 2018 Jul;16(1):211-218. doi: 10.3892/ol.2018.8684. Epub 2018 May 10.

7.

Chronic Inflammatory Microenvironment in Epidermodysplasia Verruciformis Skin Lesions: Role of the Synergism Between HPV8 E2 and C/EBPβ to Induce Pro-Inflammatory S100A8/A9 Proteins.

Podgórska M, Ołdak M, Marthaler A, Fingerle A, Walch-Rückheim B, Lohse S, Müller CSL, Vogt T, Ustav M, Wnorowski A, Malejczyk M, Majewski S, Smola S.

Front Microbiol. 2018 Mar 7;9:392. doi: 10.3389/fmicb.2018.00392. eCollection 2018.

8.

Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.

Lázaro-Frías A, Gómez-Medina S, Sánchez-Sampedro L, Ljungberg K, Ustav M, Liljeström P, Muñoz-Fontela C, Esteban M, García-Arriaza J.

J Virol. 2018 May 14;92(11). pii: e00363-18. doi: 10.1128/JVI.00363-18. Print 2018 Jun 1.

9.

Nuclear myosin 1 associates with papillomavirus E2 regulatory protein and influences viral replication.

Sankovski E, Abroi A, Ustav M Jr, Ustav M.

Virology. 2018 Jan 15;514:142-155. doi: 10.1016/j.virol.2017.11.013. Epub 2018 Jan 4.

10.

Electroporation as a vaccine delivery system and a natural adjuvant to intradermal administration of plasmid DNA in macaques.

Todorova B, Adam L, Culina S, Boisgard R, Martinon F, Cosma A, Ustav M, Kortulewski T, Le Grand R, Chapon C.

Sci Rep. 2017 Jun 23;7(1):4122. doi: 10.1038/s41598-017-04547-2.

11.

Analysis of Human Papillomavirus Genome Replication Using Two- and Three-Dimensional Agarose Gel Electrophoresis.

Henno L, Tombak EM, Geimanen J, Orav M, Ustav E, Ustav M.

Curr Protoc Microbiol. 2017 May 16;45:14B.10.1-14B.10.37. doi: 10.1002/cpmc.28.

PMID:
28510360
12.

Identification of several high-risk HPV inhibitors and drug targets with a novel high-throughput screening assay.

Toots M, Ustav M Jr, Männik A, Mumm K, Tämm K, Tamm T, Ustav E, Ustav M.

PLoS Pathog. 2017 Feb 9;13(2):e1006168. doi: 10.1371/journal.ppat.1006168. eCollection 2017 Feb.

13.

Biochemical and proteomic characterization of retrovirus Gag based microparticles carrying melanoma antigens.

Kurg R, Reinsalu O, Jagur S, Õunap K, Võsa L, Kasvandik S, Padari K, Gildemann K, Ustav M.

Sci Rep. 2016 Jul 11;6:29425. doi: 10.1038/srep29425.

14.

Increased circulating concentrations of mesencephalic astrocyte-derived neurotrophic factor in children with type 1 diabetes.

Galli E, Härkönen T, Sainio MT, Ustav M, Toots U, Urtti A, Yliperttula M, Lindahl M, Knip M, Saarma M, Lindholm P.

Sci Rep. 2016 Jun 30;6:29058. doi: 10.1038/srep29058.

15.

HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species.

Kivi G, Teesalu K, Parik J, Kontkar E, Ustav M Jr, Noodla L, Ustav M, Männik A.

BMC Biotechnol. 2016 Jan 8;16:2. doi: 10.1186/s12896-016-0232-6.

16.

Initial amplification of the HPV18 genome proceeds via two distinct replication mechanisms.

Orav M, Geimanen J, Sepp EM, Henno L, Ustav E, Ustav M.

Sci Rep. 2015 Nov 2;5:15952. doi: 10.1038/srep15952.

17.

Human Papillomavirus Type 18 cis-Elements Crucial for Segregation and Latency.

Ustav M Jr, Castaneda FR, Reinson T, Männik A, Ustav M.

PLoS One. 2015 Aug 19;10(8):e0135770. doi: 10.1371/journal.pone.0135770. eCollection 2015.

18.

Characterization of the nuclear matrix targeting sequence (NMTS) of the BPV1 E8/E2 protein--the shortest known NMTS.

Sankovski E, Karro K, Sepp M, Kurg R, Ustav M, Abroi A.

Nucleus. 2015;6(4):289-300. doi: 10.1080/19491034.2015.1074359.

19.

DNA Transfer into Animal Cells Using Stearylated CPP Based Transfection Reagent.

Karro K, Männik T, Männik A, Ustav M.

Methods Mol Biol. 2015;1324:435-45. doi: 10.1007/978-1-4939-2806-4_29.

PMID:
26202287
20.

DAXX modulates human papillomavirus early gene expression and genome replication in U2OS cells.

Kivipõld P, Võsa L, Ustav M, Kurg R.

Virol J. 2015 Jul 7;12:104. doi: 10.1186/s12985-015-0335-z.

21.

The Cell Cycle Timing of Human Papillomavirus DNA Replication.

Reinson T, Henno L, Toots M, Ustav M Jr, Ustav M.

PLoS One. 2015 Jul 1;10(7):e0131675. doi: 10.1371/journal.pone.0131675. eCollection 2015.

22.

The transcription map of HPV11 in U2OS cells adequately reflects the initial and stable replication phases of the viral genome.

Isok-Paas H, Männik A, Ustav E, Ustav M.

Virol J. 2015 Apr 14;12:59. doi: 10.1186/s12985-015-0292-6.

23.

The transcription map of human papillomavirus type 18 during genome replication in U2OS cells.

Toots M, Männik A, Kivi G, Ustav M Jr, Ustav E, Ustav M.

PLoS One. 2014 Dec 30;9(12):e116151. doi: 10.1371/journal.pone.0116151. eCollection 2014.

24.

Mapping of betapapillomavirus human papillomavirus 5 transcription and characterization of viral-genome replication function.

Sankovski E, Männik A, Geimanen J, Ustav E, Ustav M.

J Virol. 2014 Jan;88(2):961-73. doi: 10.1128/JVI.01841-13. Epub 2013 Nov 6.

25.

RIG-I and MDA-5 detection of viral RNA-dependent RNA polymerase activity restricts positive-strand RNA virus replication.

Nikonov A, Mölder T, Sikut R, Kiiver K, Männik A, Toots U, Lulla A, Lulla V, Utt A, Merits A, Ustav M.

PLoS Pathog. 2013;9(9):e1003610. doi: 10.1371/journal.ppat.1003610. Epub 2013 Sep 5.

26.

Recombination-dependent oligomerization of human papillomavirus genomes upon transient DNA replication.

Orav M, Henno L, Isok-Paas H, Geimanen J, Ustav M, Ustav E.

J Virol. 2013 Nov;87(22):12051-68. doi: 10.1128/JVI.01798-13. Epub 2013 Aug 28.

27.

New generation of efficient peptide-based vectors, NickFects, for the delivery of nucleic acids.

Arukuusk P, Pärnaste L, Oskolkov N, Copolovici DM, Margus H, Padari K, Möll K, Maslovskaja J, Tegova R, Kivi G, Tover A, Pooga M, Ustav M, Langel U.

Biochim Biophys Acta. 2013 May;1828(5):1365-73. doi: 10.1016/j.bbamem.2013.01.011. Epub 2013 Jan 26.

28.

Engagement of the ATR-dependent DNA damage response at the human papillomavirus 18 replication centers during the initial amplification.

Reinson T, Toots M, Kadaja M, Pipitch R, Allik M, Ustav E, Ustav M.

J Virol. 2013 Jan;87(2):951-64. doi: 10.1128/JVI.01943-12. Epub 2012 Nov 7.

29.

Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(®)-Multi-HIVB, in untreated HIV-1 infected subjects.

Vardas E, Stanescu I, Leinonen M, Ellefsen K, Pantaleo G, Valtavaara M, Ustav M, Reijonen K.

Vaccine. 2012 Jun 8;30(27):4046-54. doi: 10.1016/j.vaccine.2012.04.007. Epub 2012 Apr 28.

PMID:
22549090
30.

Identification and analysis of papillomavirus E2 protein binding sites in the human genome.

Võsa L, Sudakov A, Remm M, Ustav M, Kurg R.

J Virol. 2012 Jan;86(1):348-57. doi: 10.1128/JVI.05606-11. Epub 2011 Oct 26.

31.

Development of a cellular assay system to study the genome replication of high- and low-risk mucosal and cutaneous human papillomaviruses.

Geimanen J, Isok-Paas H, Pipitch R, Salk K, Laos T, Orav M, Reinson T, Ustav M Jr, Ustav M, Ustav E.

J Virol. 2011 Apr;85(7):3315-29. doi: 10.1128/JVI.01985-10. Epub 2011 Jan 19.

32.

Human papillomavirus E2 protein with single activation domain initiates HPV18 genome replication, but is not sufficient for long-term maintenance of virus genome.

Kurg R, Uusen P, Võsa L, Ustav M.

Virology. 2010 Dec 20;408(2):159-66. doi: 10.1016/j.virol.2010.09.010. Epub 2010 Oct 12.

33.

Effective formation of the segregation-competent complex determines successful partitioning of the bovine papillomavirus genome during cell division.

Silla T, Männik A, Ustav M.

J Virol. 2010 Nov;84(21):11175-88. doi: 10.1128/JVI.01366-10. Epub 2010 Sep 1.

34.

Elicitation of broad CTL response against HIV-1 by the DNA vaccine encoding artificial multi-component fusion protein MultiHIV--study in domestic pigs.

Mölder T, Adojaan M, Kaldma K, Ustav M, Sikut R.

Vaccine. 2009 Dec 11;28(2):293-8. doi: 10.1016/j.vaccine.2009.10.054. Epub 2009 Oct 29.

PMID:
19879232
35.

Persistent immune responses induced by a human immunodeficiency virus DNA vaccine delivered in association with electroporation in the skin of nonhuman primates.

Martinon F, Kaldma K, Sikut R, Culina S, Romain G, Tuomela M, Adojaan M, Männik A, Toots U, Kivisild T, Morin J, Brochard P, Delache B, Tripiciano A, Ensoli F, Stanescu I, Le Grand R, Ustav M.

Hum Gene Ther. 2009 Nov;20(11):1291-307. doi: 10.1089/hum.2009.044.

PMID:
19627235
36.

Mechanism of genomic instability in cells infected with the high-risk human papillomaviruses.

Kadaja M, Isok-Paas H, Laos T, Ustav E, Ustav M.

PLoS Pathog. 2009 Apr;5(4):e1000397. doi: 10.1371/journal.ppat.1000397. Epub 2009 Apr 24.

37.

Bovine papillomavirus type 1 E2 protein heterodimer is functional in papillomavirus DNA replication in vivo.

Kurg R, Uusen P, Sepp T, Sepp M, Abroi A, Ustav M.

Virology. 2009 Apr 10;386(2):353-9. doi: 10.1016/j.virol.2009.01.025. Epub 2009 Feb 20.

38.

Papillomavirus DNA replication - from initiation to genomic instability.

Kadaja M, Silla T, Ustav E, Ustav M.

Virology. 2009 Feb 20;384(2):360-8. doi: 10.1016/j.virol.2008.11.032. Epub 2009 Jan 13. Review.

39.

Functional characterization of fingers subdomain-specific monoclonal antibodies inhibiting the hepatitis C virus RNA-dependent RNA polymerase.

Nikonov A, Juronen E, Ustav M.

J Biol Chem. 2008 Aug 29;283(35):24089-102. doi: 10.1074/jbc.M803422200. Epub 2008 Jun 23.

40.

CuZn-SOD suppresses the bovine papillomavirus-induced proliferation of fibroblasts.

Rausalu K, Karo-Astover L, Kilk A, Ustav M.

APMIS. 2007 Dec;115(12):1415-21. doi: 10.1111/j.1600-0463.2007.00779.x.

PMID:
18184412
41.

Coinfection of Chlamydia trachomatis, Ureaplasma urealyticum and human papillomavirus among patients attending STD clinics in Estonia.

Denks K, Spaeth EL, Jõers K, Randoja R, Talpsep T, Ustav M, Kurg R.

Scand J Infect Dis. 2007;39(8):714-8.

PMID:
17654349
42.

Genomic instability of the host cell induced by the human papillomavirus replication machinery.

Kadaja M, Sumerina A, Verst T, Ojarand M, Ustav E, Ustav M.

EMBO J. 2007 Apr 18;26(8):2180-91. Epub 2007 Mar 29.

43.

High prevalence of the CCR5Delta32 HIV-resistance mutation among Estonian HIV type 1-infected individuals.

Adojaan M, Mölder T, Männik A, Kivisild T, Villems R, Krispin T, Ustav M.

AIDS Res Hum Retroviruses. 2007 Feb;23(2):193-7.

PMID:
17331026
44.

Characterization of the functional activities of the bovine papillomavirus type 1 E2 protein single-chain heterodimers.

Kurg R, Tekkel H, Abroi A, Ustav M.

J Virol. 2006 Nov;80(22):11218-25. Epub 2006 Aug 30.

45.

Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine.

Blazevic V, Männik A, Malm M, Sikut R, Valtavaara M, Toots U, Ustav M, Krohn K.

AIDS Res Hum Retroviruses. 2006 Jul;22(7):667-77.

PMID:
16831091
46.

Brd4 is involved in multiple processes of the bovine papillomavirus type 1 life cycle.

Ilves I, Mäemets K, Silla T, Janikson K, Ustav M.

J Virol. 2006 Apr;80(7):3660-5.

47.
48.
49.

Complex formation between hepatitis C virus NS2 and NS3 proteins.

Kiiver K, Merits A, Ustav M, Zusinaite E.

Virus Res. 2006 May;117(2):264-72. Epub 2005 Dec 1.

PMID:
16324764
50.

Episomal maintenance of plasmids with hybrid origins in mouse cells.

Silla T, Hääl I, Geimanen J, Janikson K, Abroi A, Ustav E, Ustav M.

J Virol. 2005 Dec;79(24):15277-88.

Supplemental Content

Support Center